X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare PLETHICO PHARMA with Sun Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PLETHICO PHARMA vs SUN PHARMA - Comparison Results

SUN PHARMA 
   Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PLETHICO PHARMA SUN PHARMA PLETHICO PHARMA/
SUN PHARMA
 
P/E (TTM) x -1.1 25.3 - View Chart
P/BV x 0.0 3.7 0.5% View Chart
Dividend Yield % 0.0 0.6 -  

Financials

 PLETHICO PHARMA   SUN PHARMA
EQUITY SHARE DATA
    PLETHICO PHARMA
Mar-14
SUN PHARMA
Mar-17
PLETHICO PHARMA/
SUN PHARMA
5-Yr Chart
Click to enlarge
High Rs395842 46.9%   
Low Rs31572 5.5%   
Sales per share (Unadj.) Rs604.4131.6 459.2%  
Earnings per share (Unadj.) Rs32.532.7 99.3%  
Cash flow per share (Unadj.) Rs51.338.0 135.2%  
Dividends per share (Unadj.) Rs03.50 0.0%  
Dividend yield (eoy) %00.5 0.0%  
Book value per share (Unadj.) Rs473.6152.7 310.1%  
Shares outstanding (eoy) m34.082,399.26 1.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.45.4 6.6%   
Avg P/E ratio x6.621.6 30.3%  
P/CF ratio (eoy) x4.218.6 22.3%  
Price / Book Value ratio x0.54.6 9.7%  
Dividend payout %010.7 0.0%   
Avg Mkt Cap Rs m7,2621,696,877 0.4%   
No. of employees `000NA17.5 0.0%   
Total wages/salary Rs m1,59649,023 3.3%   
Avg. sales/employee Rs ThNM18,028.3-  
Avg. wages/employee Rs ThNM2,798.8-  
Avg. net profit/employee Rs ThNM4,479.5-  
INCOME DATA
Net Sales Rs m20,598315,784 6.5%  
Other income Rs m3866,232 6.2%   
Total revenues Rs m20,984322,016 6.5%   
Gross profit Rs m2,818100,893 2.8%  
Depreciation Rs m64212,648 5.1%   
Interest Rs m1,5933,998 39.8%   
Profit before tax Rs m96990,479 1.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m099 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m-13812,116 -1.1%   
Profit after tax Rs m1,10778,462 1.4%  
Gross profit margin %13.731.9 42.8%  
Effective tax rate %-14.313.4 -106.7%   
Net profit margin %5.424.8 21.6%  
BALANCE SHEET DATA
Current assets Rs m18,877329,537 5.7%   
Current liabilities Rs m11,896178,870 6.7%   
Net working cap to sales %33.947.7 71.0%  
Current ratio x1.61.8 86.1%  
Inventory Days Days3679 45.5%  
Debtors Days Days19883 237.6%  
Net fixed assets Rs m9,861204,766 4.8%   
Share capital Rs m3412,399 14.2%   
"Free" reserves Rs m12,331363,997 3.4%   
Net worth Rs m16,139366,397 4.4%   
Long term debt Rs m4,70614,361 32.8%   
Total assets Rs m33,146614,102 5.4%  
Interest coverage x1.623.6 6.8%   
Debt to equity ratio x0.30 743.9%  
Sales to assets ratio x0.60.5 120.9%   
Return on assets %8.113.4 60.7%  
Return on equity %6.921.4 32.0%  
Return on capital %12.324.8 49.5%  
Exports to sales %21.40-   
Imports to sales %15.20-   
Exports (fob) Rs m4,402NA-   
Imports (cif) Rs m3,136NA-   
Fx inflow Rs m4,40244,118 10.0%   
Fx outflow Rs m3,18424,484 13.0%   
Net fx Rs m1,21919,634 6.2%   
CASH FLOW
From Operations Rs m2,43770,822 3.4%  
From Investments Rs m-6,265-42,216 14.8%  
From Financial Activity Rs m2,490-22,854 -10.9%  
Net Cashflow Rs m-1,3376,107 -21.9%  

Share Holding

Indian Promoters % 82.7 63.7 129.8%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 4.3 5.1 83.8%  
FIIs % 5.5 23.0 23.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 7.5 8.3 90.4%  
Shareholders   10,665 133,026 8.0%  
Pledged promoter(s) holding % 85.7 0.5 16,177.4%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PLETHICO PHARMA With:   SUVEN LIFE  ORCHID PHARMA LTD  SANOFI INDIA  TTK HEALTHCARE  MERCK LTD  

Compare PLETHICO PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Weak Start to the Week; PSU & Metal Stocks Fall(Closing)

Indian share markets continued to witness selling pressure in the afternoon session as benchmark Sensex slipped below the 34,000-mark.

Related Views on News

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Sun Pharma: Price Erosion in US Impacts Growth (Quarterly Results Update - Detailed)

May 30, 2017

US markets decline while other geographies grow in the quarter.

Sun Pharma: Slow Growth Across Major Markets (Quarterly Results Update - Detailed)

Mar 11, 2017

Sun Pharma has announced its December quarter (3QFY17) results. The company has reported 8% YoY growth in sales and a decline of 4.7% YoY in the net profits.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

More Views on News

Most Popular

Here's What You Should Do in this Market Crash(The 5 Minute Wrapup)

Feb 6, 2018

The market correction has provided a golden opportunity to buy five high-quality safe stocks.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

When Small is Not Always Beautiful(Chart Of The Day)

Feb 6, 2018

Big companies enjoying tax deductions and exemptions have an edge over the small companies.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PLETHICO PHARMA SHARE PRICE


Jun 13, 2016 (Close)

TRACK PLETHICO PHARMA

  • Track your investment in PLETHICO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PLETHICO PHARMA

PLETHICO PHARMA 8-QTR ANALYSIS

COMPARE PLETHICO PHARMA WITH

MARKET STATS